Medicine Information

Daprogen

Name: Daprogen
Brand: Daprogen
Rating: 4.5 (117 reviews)

Tablet4 mgAntidiabetic, SGLT2 InhibitorATC: A10BK0X

Generic Name

Daprogen 4 mg Tablet

Manufacturer

GenericPharma Inc.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
daprogen 4 mg tablet	৳ 90.00	৳ 900.00

Description

Overview of the medicine

Daprogen 4 mg Tablet is an oral antidiabetic medication belonging to the SGLT2 inhibitor class. It is primarily used to improve glycemic control in adults with type 2 diabetes mellitus, and also indicated for reducing the risk of cardiovascular death and hospitalization for heart failure, and slowing the progression of kidney disease.

Uses & Indications

Type 2 Diabetes Mellitus: As an adjunct to diet and exercise to improve glycemic control.

Heart Failure: To reduce the risk of cardiovascular death and hospitalization for heart failure in adults.

Chronic Kidney Disease: To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults.

Dosage

Adults

The recommended starting dose is Daprogen 4 mg once daily, taken orally in the morning, with or without food. The dose may be increased based on efficacy and tolerability, up to a maximum of 8 mg once daily.

Elderly

No dose adjustment is required based on age alone. However, renal function should be monitored, as elderly patients may have reduced renal function.

Renal_impairment

For patients with eGFR ≥ 45 mL/min/1.73m², no dose adjustment is needed. For eGFR < 45 mL/min/1.73m², Daprogen is not recommended for glycemic control. For heart failure and chronic kidney disease indications, initiation is not recommended if eGFR < 25 mL/min/1.73m².

How to Take

Take Daprogen 4 mg Tablet orally once daily in the morning, with or without food. Swallow the tablet whole with water. Do not crush, break, or chew the tablet.

Mechanism of Action

Daprogen selectively inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal tubules, reducing glucose reabsorption and increasing urinary glucose excretion, thereby lowering blood glucose levels. It also has beneficial effects on blood pressure and body weight.

Pharmacokinetics

Onset

Glycosuric effect observed within 30 minutes of administration; blood glucose lowering effects within a few hours.

Excretion

Approximately 70% excreted in urine (primarily as metabolites) and 30% in feces (mostly as unchanged drug).

Half life

Approximately 10-14 hours, supporting once-daily dosing.

Absorption

Rapidly absorbed after oral administration, with peak plasma concentrations reached within 1-2 hours. Absolute bioavailability is approximately 85%.

Metabolism

Primarily metabolized in the liver via O-glucuronidation by UGT1A9 to inactive metabolites.

Side Effects

Contraindications

Hypersensitivity to the active substance or to any of the excipients.
Severe renal impairment (eGFR < 25 mL/min/1.73m²) for initiation for heart failure/CKD, or eGFR < 45 mL/min/1.73m² for glycemic control.
End-stage renal disease (ESRD) or patients on dialysis.

Drug Interactions

Diuretics

Co-administration with diuretics may increase the risk of dehydration and hypotension. Close monitoring of volume status and blood pressure is recommended.

ACE Inhibitors/ARBs

No clinically significant pharmacokinetic interactions, but caution with concomitant use due to potential additive hypotensive effects.

Insulin and Insulin Secretagogues (e.g., Sulfonylureas)

May increase the risk of hypoglycemia. A lower dose of insulin or an insulin secretagogue may be required.

Storage

Store below 30°C in a dry place, away from direct light and moisture. Keep out of reach of children.

Overdose

In the event of an overdose, symptomatic and supportive treatment should be initiated. Daprogen is not expected to be dialyzable.

Pregnancy & Lactation

Daprogen is not recommended during pregnancy, especially during the second and third trimesters, due to potential adverse effects on fetal renal development. It is also not recommended during lactation, as it is unknown if Daprogen is excreted in human milk.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

10 tablets per blister, 3 blisters per carton (30 tablets)5 tablets per blister, 6 blisters per carton (30 tablets)

Shelf Life

24 months from the date of manufacture.

Availability

Available in pharmacies and hospitals

Approval Status

Approved by FDA and DGDA

Patent Status

Under patent

Clinical Trials

Daprogen has successfully completed multiple Phase III clinical trials demonstrating its efficacy and safety in type 2 diabetes, heart failure, and chronic kidney disease. Ongoing post-marketing surveillance and Phase IV studies are monitoring long-term outcomes.

Lab Monitoring

Renal function (eGFR) should be assessed before initiating Daprogen and periodically thereafter.
Blood glucose levels should be monitored regularly to assess glycemic control.
Electrolytes (especially potassium) should be monitored in patients at risk of electrolyte imbalance.

Doctor Notes

Assess eGFR before initiating and regularly during treatment. Discontinue if eGFR falls below recommended thresholds for specific indications.
Educate patients on symptoms of DKA and the importance of hydration. Advise temporary discontinuation during acute illness or surgery.
Monitor for signs of volume depletion, especially in patients on diuretics or with pre-existing renal impairment.

Patient Guidelines

Take Daprogen exactly as prescribed by your doctor.
Maintain adequate hydration to prevent dehydration.
Report any symptoms of genital or urinary tract infections, or symptoms of DKA (e.g., nausea, vomiting, abdominal pain, excessive thirst, unusual fatigue) to your doctor immediately.

Missed Dose Advice

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses at once to make up for a missed dose.

Driving Precautions

Daprogen itself is not expected to impair the ability to drive or operate machinery. However, patients experiencing symptoms like dizziness due to dehydration or hypoglycemia (especially when combined with insulin or sulfonylureas) should exercise caution.

Lifestyle Advice

Maintain a balanced diet and regular exercise routine as advised by your healthcare provider.
Limit alcohol intake, as excessive alcohol can increase the risk of ketoacidosis.
Monitor your blood sugar levels regularly and keep a record.